InflaRx N.V.
izicopan
hidradenitis suppurativa (HS)
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews izicopan for hidradenitis suppurativa (HS) around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 14h ago
“InflaRx has largely concluded its interactions with FDA regarding an optimized clinical development program for izicopan in HS, and believes a viable path forward exists.”